Abstract: Human T-cell leukemia virus (HTLV)-1 is a human retrovirus and the etiological agent of adult T-cell leukemia/lymphoma (ATLL), a fatal malignancy of CD4/CD25+ T lymphocytes. In recent years, cellular as well as virus-encoded microRNA (miRNA) have been shown to deregulate signaling pathways to favor virus life cycle. HTLV-1 does not encode miRNA, but several studies have demonstrated that cellular miRNA expression is affected in infected cells. Distinct mechanisms such as transcriptional, epigenetic or interference with miRNA processing machinery have been involved. This article reviews the current knowledge of the role of cellular microRNAs in virus infection, replication, immune escape and pathogenesis of HTLV-1.
Introduction
The transmission of the human T-cell leukemia virus (HTLV-1) retrovirus requires close contact with infected T cells, and occurs from mother to child, predominantly through breastfeeding as well as through sexual contact and blood transfusion [1, 2] . The HTLV-1 infection is also associated with other diseases, such as: a chronic and progressive neurologic disorder named HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), polymyositis, infective dermatitis, HTLV-1 associated arthropathy, The authors have demonstrated a direct interaction between the Tax oncoprotein and Drosha, which is responsible for its downregulation. The N-terminal region of Tax presents two putative motifs, the Zinc finger motif and leucine-zipper-like region, which interact with Drosha. The Tax N-terminal region is reported to interact with the proteasome complex. Van Duyne and colleagues demonstrated that the binding between Tax and Drosha leads to its degradation mediated by proteasome complex. In addition, Drosha increases HTLV-1 replication and is not efficient in processing miRNAs when Tax is expressed, suggesting that the dysregulation of miRNA machinery might be involved in the rate of HTLV-1 infection [38] . The HTLV-1 regulatory protein, Rex, is reported to directly interact with Dicer. Abe [39] and colleagues have demonstrated that Rex suppresses the ribonuclease-directed processing activity of Dicer, protecting against the cleavage Rex-mRNA (Figure 1 ). Inhibition of Dicer activation might represent an additional mechanism used by HTLV-1 to deregulate cellular miRNA expression.
MiRNAs Target the HTLV-1 Genome
The cellular environment has an essential role in virus infection and replication. Many cellular genes prevent replication and virus dissemination by acting as innate immunity factors. However, viruses have evolved strategies to avoid activation of an antiviral state: virus-derived miRNAs can enhance viral gene expression, replication, and infectivity [40] or suppress the IFN response [41] . The genome of the Epstein-Barr virus (EBV), Kaposi sarcoma-associated herpesvirus (KSHV), human cytomegalovirus (hCMV) and bovine leukemia virus (BLV) encodes for virus-derived miRNAs [42] [43] [44] [45] . BLV shares many characteristics in disease pathogenesis with HTLV-1 and is associated with the development of B-cell tumors. Kincaid and colleagues [45] show that BLV is capable of producing miRNAs in vitro. A subsequent study demonstrated that BLV encodes a conserved cluster of miRNAs located in a specific BLV proviral region, which is essential for in vivo infectivity [46] . BLV has different common features in genomic organization with HTLV-1, however HTLV-1-encoded miRNAs have not been reported. Cellular miRNAs can promote virus replication or negatively regulate virus expression and infectivity [47] . MiR-28, miR-125b, together with miR-150, miR-223 and miR-382 target 3 1 ends of HIV-1 messenger, promoting viral latency [47] . Bai and colleagues identified a binding site in the HTLV-1 genome for miR-28-3p and demonstrated a mechanism used by a cellular miRNA to prevent HTLV-1 gene expression and viral transmission ( Figure 2 ) [48] . MiR-28-3p was found to target a sequence localized within the viral gag/pol HTLV-1 mRNA and reduced viral replication and gene expression. MiR-28-3p-expressing cells are characterized by reduced levels of HTLV-1 gag p19 and p24 products and they are resistant to infection. MiR-28-3p expression leads to abortive infection by inhibiting HTLV-1 reverse transcription and preventing the formation of the pre-integration complex. MiR-28-3p suppresses HTLV-1 expression and infection; this is consistent with the high levels of miR-28-3p reported in resting T cells and their inability to be infected by HTLV-1 without prior activation. Bai and colleagues [48] demonstrated a natural feedback loop that regulated miR-28-3p expression in response to virus infection. It is well established that de novo infection in T cells activates the interferon anti-viral response. MiR-28-3p expression was found to be induced after IFN-α or -γ stimulation, suggesting that miR-28-3p might contribute to restricting virus expansion to neighboring cells by reducing local inflammation and the initial establishment of latent infection. The miR-28-3p site is highly conserved in HTLV-1 subtypes B and C, at nearly 90%.
However, the subtype 1A, Japanese ATK-1, presents a natural polymorphism (T to C substitution) within the miR-28-3p target site. The mutation is silent and more resistant to miR-28-3p inhibition of viral replication. Bai and colleagues [48] proposed a model where the modulation of miR-28-3p expression affected HTLV-1 virus spreading. Virus particles can transiently activate resting T cells by reducing miR-28-3p expression and favoring infection. Because IFN response is a potent inducer of miR-28-3p expression, the initial antiviral response might backfire, helping to protect newly infected cells from being eliminated by the immune system.
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MiRNAs Promote Cell Proliferation

MiR-146a
MiR-146a has a central role in the regulation of immune response and its expression is induced by NF-κB signaling. MiR-146a is deregulated in different cancers. A high level of expression was reported in papillary thyroid carcinoma, anaplastic thyroid cancer, breast cancer, glioblastoma and cervical cancer [49] [50] [51] [52] [53] . In contrast, low-expressing levels were described in pancreatic carcinoma, gastric cancer, prostate cancer, acute myeloid leukemia (AML), myeloblastic syndrome and chronic myeloid leukemia (CML) [54] [55] [56] [57] [58] [59] . MiR-146a was found to be upregulated in HTLV-1-transformed cell lines [27] . Ectopic expression of Tax in HTLV-1-negative T cells, Jurkat, induced miR-146a expression. Promotor analysis showed a 15-fold activation of miR-146a by Tax [60] , suggesting that HTLV-1 infection might be involved in the regulation of miR-146a expression. Pichler [27] and colleagues used a mutated form of Tax and dominant active NF-κB inhibitor to show that miR-146a transactivation is mediated by NF-κB ( Figure 3 ).
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MiR-146a has a central role in the regulation of immune response and its expression is induced by NF-κB signaling. MiR-146a is deregulated in different cancers. A high level of expression was reported in papillary thyroid carcinoma, anaplastic thyroid cancer, breast cancer, glioblastoma and cervical cancer [49] [50] [51] [52] [53] . In contrast, low-expressing levels were described in pancreatic carcinoma, gastric cancer, prostate cancer, acute myeloid leukemia (AML), myeloblastic syndrome and chronic myeloid leukemia (CML) [54] [55] [56] [57] [58] [59] . MiR-146a was found to be upregulated in HTLV-1-transformed cell lines [27] . Ectopic expression of Tax in HTLV-1-negative T cells, Jurkat, induced miR-146a expression. Promotor analysis showed a 15-fold activation of miR-146a by Tax [60] , suggesting that HTLV-1 infection might be involved in the regulation of miR-146a expression. Pichler [27] and colleagues used a mutated form of Tax and dominant active NF-κB inhibitor to show that miR-146a transactivation is mediated by NF-κB ( Figure 3 ). Tomita et al. [60] also reported an NF-κB binding site on the miR-146a gene. In addition, it has been described as having a suppressive effect of miR-146a on NF-κB signaling [51] . This might represent a negative feedback loop, which seems to be ineffective in HTLV-1-infected cells. MiR-146a has also been shown to induce proliferation in several human cancers, including cervical cancer [53] , breast cancer cells [61] , gastric cancer cells [62] and mesenchymal stem cells (MSCs) [63] . Consistent with this report, treatment with an anti-miR-146a inhibitor suppressed the proliferation of HTLV-1-transformed cell lines but not uninfected T-cell lines. In addition, overexpression of miR-146a increased the growth of HTLV-1-transformed cell lines [27] . Because overexpression of miR-146a has also been described in an EBV context, Tomita [60] and colleagues suggested that miR-146a up-regulation might represent a common mechanism in the pathogenesis of persistent viruses. Wang et al. [64] identified 622 putative target genes of miR-146a that are predicted by using different prediction programs. Gene ontology analysis shows that these genes are involved in the inhibition of cell growth and promotion of apoptosis, and this partially explains the role of miR-146a in the proliferation of HTLV-1-transformed cells.
MiR-155
MiR-155 has been implicated in normal hematopoiesis [65] , immune response [66] , and in the carcinogenesis of different human tumors [67, 68] . Mouse studies have reported that transgenic overexpression of miR-155 results in the increased frequency of tumor formation [69] . Overexpression of miR-155 was found in breast cancer [70] , pancreatic cancer [71] , lung cancer [72] , B-cell lymphoma [67] , MALT lymphoma [73] and acute myeloid leukemia (AML) [74] . MiR-155 was found elevated in HTLV-1-infected cells in vitro and in vivo [28, 75] , suggesting that this miRNA might play an important role in the biology and pathogenesis of HTLV-1. Babar [76] and colleagues used an inducible knock-in mouse model to show that miR-155 induction in the lymphoid tissue led to disseminated lymphoma. In contrast, reduction of miR-155 resulted in the decrease of tumor size. In humans, Calin [77] and colleagues identified a miRNA signature associated with progression and prognosis in chronic lymphocytic leukemia (CLL) and showed an association between miR-155 upregulation and poor prognosis. Several lymphoma-associated viruses, including the Epstein-Barr virus, Kaposi sarcoma-associated herpesvirus and Marek's disease virus, are characterized by overexpression of miR-155 [73, 78] , suggesting that HTLV-1 infection might be responsible for the induction of miR-155 in infected T cells. MiR-155 upregulation has been reported in HTLV-1 cell lines and ATLL patients [28, 75] . Tomita [75] and colleagues demonstrated that transcription factors NF-κB and AP-1 induced miR-155 expression by binding the miRNA promoter in an HTLV-1 context (Figure 3 ). This binding resulted in an increased expression of the B-cell integration cluster (BIC) gene whose transcript is processed into miR-155 ( Figure 3 ). Tomita and colleagues demonstrated that miR-155 overexpression enhanced the growth in HTLV-1-transformed cells. Consistently, treatment with anti-miR-155 reduced the proliferation of these cells and had no effect on HTLV-1-negative T cells. Wang [79] and colleagues demonstrated that interferon regulatory factor-4, IRF4, which is reported to be oncogenic [80] , induces BIC/miR-155 expression in HTLV-1-transformed cells (Figure 3) . In normal lymphocytes, IRF4 is involved in cellular proliferation and differentiation [80] . In mature human CD4+ T cells, IRF4 is essential for cytokine production and survival [81, 82] . Several studies show that IRF4 is overexpressed in HTLV-1-transformed and primary ATLL/L cells and associated with poor prognosis [81] [82] [83] , suggesting that IRF4 might be involved in HTLV-1 pathogenesis. Wang and colleagues show that depletion of IRF4 drastically reduced cell proliferation of HTLV-1-transformed cell lines, suggesting that the IRF4/miR-155 pathway might play a central role in the malignant proliferation of HTLV-1-infected cells [80] . In addition, miR-155 is reported to target Tumor Protein 53-Induced Nuclear Protein 1 (TP53INP1) in liver cancer stem cells [84] , which promotes cell cycle arrest and apoptosis, suggesting a possible mechanism that could enhance cellular proliferation in an HTLV-1 context.
MiR-150 and MiR-223
MiR-150 and miR-223 were reported to be differentially regulated in HTLV-1-transformed cells and in ATLL samples. MiR-150 and miR-223 were found upregulated in acute ATLL patients and downregulated in HTLV-1-transformed cell lines, suggesting that different selective pressure in vitro and in vivo might regulate the expression of those miRNAs. MiR-150 can have either oncogenic or tumor suppressor activity in different human tumors. It is overexpressed in chronic lymphocytic leukemia (CLL) [85, 86] and downregulated in chronic myeloid leukemia (CML) [87, 88] , acute lymphoblastic leukemia (ALL) [89] and mantle cell lymphoma (MCL) [90] . Additional studies show that miR-150 promotes the proliferation and migration in lung cancer by targeting SRC kinase signaling inhibitor 1 (SRCIN1) and SRC activity [91] . In contrast, miR-150 expression was reported to inhibit cell migration and invasion in breast cancer [92, 93] . C-MYB, NOTCH3, CBL, EGR2, AKT2 and DKC1 are established targets of miR-150 [94] [95] [96] [97] [98] . MiR-223 was reported to be differentially regulated in human cancers; it is downregulated in hepatocellular carcinoma, B-cell chronic lymphocytic leukemia (B-CLL), acute myeloid leukemia (AML), gastric MALT lymphoma and recurrent ovarian cancer [99] [100] [101] [102] [103] . In contrast, miR-223 is upregulated in T-cell acute lymphocytic leukemia (T-ALL), EBV-positive diffuse large B-cell lymphoma, and metastatic gastric cancer [104] [105] [106] [107] [108] . FBXW7/Cdc4, RhoB, STMN1, E2F1, STAT3, C/EBPβ, FOXO1 and NFI-A are validated targets of miR-223 [106] [107] [108] [109] [110] [111] . It has previously been shown that E2F1 represses the miR-223 promoter [110] [111] [112] . Interestingly, viral HBZ mRNA increases the expression and transcriptional activity of E2F1. HBZ expression is consistently increased in ATLL cells in vivo [11] . These observations can partially explain the differential regulation of miR-223 in vitro and in vivo. MiR-150 and miR-223 target the STAT1 3 1 UTR in an HTLV-1 context (Figure 3 ). STAT1 plays an essential role in immune modulatory functions, anti-viral responses, apoptosis and anti-proliferative responses [113] . In addition, several studies have shown that STAT1 can also act as a potent tumor promoter for leukemia development [114] and that many T-ALL leukemic cells are dependent upon the TYK2-STAT1-BCL2 pathway for continued survival [115] . Inverse correlation between STAT1 expression and miR-150 and miR-223 was identified in HTLV-1-transformed and IL-2-independent ATLL-derived cells [116] . IL-2-dependent ATLL cells display a high level of miR-150 expression, but low miR-223, suggesting that miR-150 might be regulated through the IL-2 signaling pathway. 
MiRNAs Induce Resistance to Apoptosis
MiR-31
Yamagishi [30] and colleagues identified miR-31 as one of the most profoundly repressed miRNAs in primary ATLL cells. MiR-31 is reported as a tumor suppressor and correlates inversely with metastasis in breast cancer [117] . MiR-31 in vivo targets several genes, such as Fzd3, ITGA5, MMP16, RDX, RhoA, WAVE3 and integrin α5 subunit, that contribute to cell migration and metastatic invasion [117, 118] . The Polycomb protein complex has been reported to be a strong suppressor of miR-31 in breast cancer and adult T-cell leukemia [30, 117] . Polycomb group proteins are overexpressed in ATLL cells [119] and have an important role in cellular development and regeneration by controlling histone methylation, especially at histone H3 Lys27 (H3K27), which induces chromatin compaction. The Polycomb family is associated with cancer phenotypes and malignancy in breast cancer, prostate cancer, bladder tumors, and other neoplasms [120, 121] . MiR-31 negatively regulates NF-κB-inducing kinase (NIK) expression and activity in adult T-cell leukemia and other cancers [30] . NIK has an important role in tumor progression and the aggressive phenotypes of various cancers. It is well established that the NIK level directly regulates NF-κB activity in various cell types [122] . Constitutive activation of the nuclear factor NF-κB is observed in the ATLL cell lines and primary isolated tumor cells from ATLL patients [123] . NF-κB activation contributes to cell propagation and anti-apoptotic responses in ATLL [124] . An inverse correlation has been reported between the expression level of miR-31 and NIK in ATLL patients. Rescue of miR-31 represses NF-κB expression and leads to increased proliferation and apoptosis resistance. The inhibition of NF-kB promotes tumor cell death in HTLV-1-transformed cells and primary ATLL cells. The model proposed by Yamagishi and colleagues show that the Polycomb group regulates miR-31 expression and leads to NF-κB activation via NIK-miR-31 regulation and apoptosis resistance in HTLV-1 context (Figure 4) . The downregulation of miR-31 might play an important role in ATLL pathogenesis.
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MiR-130b and MiR-93
Microarray analyses demonstrated that miR-130b and miR-93 were consistently upregulated in HTLV-1 cell lines and ATLL patients and both target Tumor protein p53-inducible nuclear protein, TP53INP1 [29] . MiR-130b was found to be deregulated in several human cancers. Overexpression of miR-130b has been reported in colorectal cancer, gastric cancer, bladder cancer, cutaneous malignant Figure 4 . MiRNAs induce resistance to apoptosis. MiR-31 is one of the most profoundly repressed miRNAs in primary ATLL cells. The Polycomb protein complex is overexpressed in ATLL cells and suppresses miR-31 expression. MiR-31 negatively regulates NF-κB-inducing kinase (NIK) and leads to apoptosis resistance. MiR-130b and miR-93 are upregulated in HTLV-1 cell lines and ATLL patients and both target Tumor protein p53-inducible nuclear protein (TP53INP1). TP53INP1 is a tumor suppressor gene that has anti-proliferative and pro-apoptotic activities via both p53-dependent and p53-independent means. TP53INP1 has in its 3 1 UTR two binding sites for miR-93 and two sites for miR-130b.
Microarray analyses demonstrated that miR-130b and miR-93 were consistently upregulated in HTLV-1 cell lines and ATLL patients and both target Tumor protein p53-inducible nuclear protein, TP53INP1 [29] . MiR-130b was found to be deregulated in several human cancers. Overexpression of miR-130b has been reported in colorectal cancer, gastric cancer, bladder cancer, cutaneous malignant melanoma, and head and neck squamous cell carcinoma [125] [126] [127] [128] . In contrast, miR-130b is downregulated in papillary thyroid carcinoma, ovarian cancer and endometrial cancer [129] [130] [131] [132] . Identified targets of miR-130b are STAT3, PTEN and TGF-b1 [133] [134] [135] . MiR-93 belongs to the miR-106b-25 cluster, which also includes miR-106b and miR-25 [136] . The miR-106b-25 cluster is overexpressed in neuroblastoma, multiple myeloma, and lung, prostate and gastric tumors [136] [137] [138] . Reported targets of miR-93 are PTEN, VEGF, ITGB8, DAB2 and LATS2 [139] [140] [141] [142] [143] . TP53INP1 is a tumor suppressor gene that has anti-proliferative and pro-apoptotic activities via both p53-dependent [144] and p53-independent means [145] . TP53INP1 has in its 3 1 UTR two binding sites for miR-93 and two sites for miR-130b. Yeung [29] and colleagues have shown that transfection of antagomirs against miR-93 and miR-130b into an HTLV-1-transformed cell line increased the expression of TP53INP1 and decreased cellular viability by promoting apoptosis (Figure 4) . These results show that TP53INP1 has anti-proliferative properties and can be regulated by miR-130b and miR-93. Transfection of miR-93 or miR-130b in HTLV-1-negative T-cell lines reduced TP53INP1 expression and increased cellular proliferation. It has been reported that loss of TP53INP1 correlates with the development of cancers [146, 147] and its induction promotes G1 cell cycle arrest and apoptosis [144, 145, 148] . This evidence suggests that up-regulation of miR-130b and miR-93 reduces TP53INP1 levels in ATLL cells and promotes cellular proliferation. TP53INP1 is also able to reduce cell migration in pancreatic cancer cells [149] and this might be significant because it is well established that HTLV-1 infection promotes T-lymphocyte migration [150] .
MiRNAs Promote Chromatin Remodeling
The Tax protein promotes HTLV-1 gene expression by its interaction with the long terminal repeat (LTR) or U3 region of the viral promoter [151, 152] . To activate the transcription, Tax recruits the p300/CREB-binding protein (p300/CBP) and p300/CBP-associated factor (P/CAF), which bind two different regions of Tax, resulting in histone acetylation and chromatin remodeling ( Figure 5 ) [153] [154] [155] [156] [157] [158] . Rahman [157] and colleagues identified the chromatin remodeling factors, p300 and p/CAF, as a target of miR-149 and miR-873. MiR-149 has been reported to have a role as an oncogene and tumor suppressor in different human cancers [158, 159] . Downregulation of miR-149 has been described in prostatic cancer, astrocytomas and renal carcinoma [160] [161] [162] . In contrast, miR-873 was found to be suppressed in colorectal cancer, glioblastoma and breast cancer [163] [164] [165] . Recent evidence has established the role of miR-873 in cell proliferation, tumor growth and tamoxifen resistance in breast cancer [165] . MiR-149 and miR-873 were found to be profoundly downregulated in HTLV-1-transformed cell lines, MT-2, compared to an uninfected control, Jurkat [157] . To verify that miR-149 and miR-873 could target p/CAF and p300, the authors over-expressed these miRNAs in HTLV-1-transformed cells and observed a significant reduction in the expression of chromatin-remodeling enzymes. In addition, the cell culture supernatant was analyzed for viral protein p19 before and after transfection. The results show a decrease in the levels of viral progeny production in cells transfected with miR-149 and miR-873, suggesting that these miRNAs, by targeting chromatin remodeling factors p/CAF and p300, might play a role in HTLV-1 infection and pathogenesis ( Figure 5 ). To activate the transcription, Tax recruits the p300/CREB-binding protein (p300/CBP) and p300/CBP-associated factor (P/CAF), which bind two different regions of Tax, resulting in histone acetylation and chromatin remodeling. MiR-149 and miR-873 are downregulated in HTLV-1-transformed cell lines and target the chromatin remodeling factors p300 and p/CAF.
MiRNAs Induce Genetic Instability
MiRNA expression analysis in CD4+ lymphocytes, derived from HAM/TSP patients, has identified a high expression level of miR-17 and miR-21 [166] . Spry 1, Spry 2, PTEN, TPM1 and Pdcd4 have been reported to be miR-21 targets, suggesting its central role in cell proliferation, apoptosis, and invasion [167] [168] [169] [170] [171] . MiR-17, instead, is the main effector of the miR-17-92 cluster component, which has been identified as a member of the miRNA signature in solid tumors [172] . MiR-17 regulates E2F1 and c-Myc, p21, PTEN and BIM expression [173] [174] [175] [176] , suggesting its potential functions in cell migration, invasion and proliferation. Vernin [166] and colleagues identified OBFC2A as a potential target of miR-17 and miR-21 in an HTLV-1 context. OBFC2A encodes for hSSB2, which is involved in the ATM signaling pathway, the activation of the cell cycle checkpoint and promotes DNA repair. The down-regulation of OBFC2A and a positive correlation between miR-17, miR-21 and HBZ expression Figure 5 . MiR-149 and miR-873 promote chromatin remodeling. The Tax protein promotes HTLV-1 gene expression by its interaction with the long terminal repeat (LTR) or U3 region of the viral promoter. To activate the transcription, Tax recruits the p300/CREB-binding protein (p300/CBP) and p300/CBP-associated factor (P/CAF), which bind two different regions of Tax, resulting in histone acetylation and chromatin remodeling. MiR-149 and miR-873 are downregulated in HTLV-1-transformed cell lines and target the chromatin remodeling factors p300 and p/CAF.
MiRNA expression analysis in CD4+ lymphocytes, derived from HAM/TSP patients, has identified a high expression level of miR-17 and miR-21 [166] . Spry 1, Spry 2, PTEN, TPM1 and Pdcd4 have been reported to be miR-21 targets, suggesting its central role in cell proliferation, apoptosis, and invasion [167] [168] [169] [170] [171] . MiR-17, instead, is the main effector of the miR-17-92 cluster component, which has been identified as a member of the miRNA signature in solid tumors [172] . MiR-17 regulates E2F1 and c-Myc, p21, PTEN and BIM expression [173] [174] [175] [176] , suggesting its potential functions in cell migration, invasion and proliferation. Vernin [166] and colleagues identified OBFC2A as a potential target of miR-17 and miR-21 in an HTLV-1 context. OBFC2A encodes for hSSB2, which is involved in the ATM signaling pathway, the activation of the cell cycle checkpoint and promotes DNA repair. The down-regulation of OBFC2A and a positive correlation between miR-17, miR-21 and HBZ expression has been reported in HTLV-1-infected cells [166] . Vernin and colleagues suggested that HBZ inactivates OBFC2A via miR-17 and miR-21, promoting genetic instability and cell proliferation ( Figure 6 ).
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has been reported in HTLV-1-infected cells [166] . Vernin and colleagues suggested that HBZ inactivates OBFC2A via miR-17 and miR-21, promoting genetic instability and cell proliferation ( Figure 6 ). Figure 6 . MiRNAs induce genetic instability. MiR-17 and miR-21 are upregulated in an HTLV-1 context. HBZ inactivates OBFC2A via miR-17 and miR-21, promoting genetic instability and cell proliferation. OBFC2A encodes for hSSB2, which is involved in the ATM signaling pathway, the activation of the cell cycle checkpoint and promotes DNA repair.
The authors have shown that ectopic expression of HBZ does not decrease cellular growth in DNA-damaged cells. HBZ-expressing cells continued to proliferate when treated with a DNA-damaging agent, neocarzinostatin. This phenotype can be reversed by ectopic expression of OBFC2A, which leads to a decrease of proliferation rates and restores the DNA damage response. This evidence suggested a potential role of miR-17 and miR-21 in genetic instability and cell proliferation in HTLV-1-infected cells. The authors have shown that ectopic expression of HBZ does not decrease cellular growth in DNA-damaged cells. HBZ-expressing cells continued to proliferate when treated with a DNA-damaging agent, neocarzinostatin. This phenotype can be reversed by ectopic expression of OBFC2A, which leads to a decrease of proliferation rates and restores the DNA damage response. This evidence suggested a potential role of miR-17 and miR-21 in genetic instability and cell proliferation in HTLV-1-infected cells.
Conclusions and Prospective
The role of miRNAs in HTLV-1 infection and ATLL pathogenesis is beginning to emerge. Available evidence shows a complex interplay between cellular miRNA machinery and virus infection. HTLV-1 inhibits proteins involved in biogenesis and maturation of cellular miRNAs, resulting in a perturbation of the expression profile of host miRNAs. In this review, we focused on miRNAs, which are involved in virus production, establishment of latency, tumor cell transformation and proliferation. A potential role of MiRNA modulation could represent a therapeutic approach for ATLL patients. The combination delivery of miRNAs with chemotherapy drugs might provide a promising strategy to overcome chemo-resistance. Different studies have shown that co-delivery of miRNA and chemotherapeutic agents are effective to inhibit tumor growth by targeting genes, which are involved in tumor cell proliferation and/or survival [177] [178] [179] . In addition, in combination with antitumor drugs, miRNAs might have an important role by targeting genes involved in drug resistance, thus overcoming the chemo-resistance in ATLL patients.
